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Abstract: Thioredoxin reductase (TR) and thioredoxin (Trx) defi ne 
a major cellular redox system that maintains cysteine residues in nu-
merous proteins in the reduced state. Both cytosolic (TR1 and Trx1) 
and mitochondrial (TR3 and Trx2) enzymes are essential in mam-
mals, but the function of the mitochondrial system is less understood. 
In this study, we characterized subcellular localization of three TR3 
forms that are generated by alternative fi rst exon splicing and that dif-
fer in their N-terminal sequences. Only one of these forms resides in 
mitochondria, whereas the two other isoforms are cytosolic. Consis-
tent with this fi nding, TR3 did not have catalytic preferences for mi-
tochondrial Trx2 versus cytosolic Trx1, both of which could serve as 
TR3 substrates. Similarly, TR1 was equally active with Trx1, Trx2, 
or a bacterial Trx. We generated recombinant selenoprotein forms of 
TR1 and TR3 and found that these enzymes were inhibited by zinc, 
but not by calcium or cobalt ions. We further developed a proteomic 
method for identifi cation of targets of TRs in mammalian cells utiliz-
ing affi nity columns containing recombinant TR3 forms differing in 
C-terminal sequences. Using this procedure, we found that Trx1 was 
the major target of TR3 in both rat and mouse liver cytosol. The trun-
cated form of TR3 lacking selenocysteine was particularly effi cient 
in binding Trx1, consistent with the previously observed role of trun-
cated TR1 in apoptosis. Overall, these data establish that the function 
of TR3 is not limited to its role in Trx2 reduction. 
Abbreviations: Trx, thioredoxin; TR, thioredoxin reductase; m, 
mouse; EGFP, enhanced green fl uorescent protein; Sec, selenocyste-
ine; SECIS, selenocysteine insertion sequence; h, human; r, rat; PBS, 
phosphate-buffered saline; DTT, dithiothreitol; EST, expressed se-
quence tag.
Introduction 
The thioredoxin (Trx) system is one of the key cellular redox reg-
ulators (1). Together with the glutathione system, it controls the re-
dox state of Cys residues in proteins and has numerous other roles in 
redox regulation of cellular processes. The Trx system is composed 
of thioredoxin reductase (TR) and Trx. TR is an FAD-containing pyr-
idine nucleotide-disulfi de oxidoreductase. It transfers electrons from 
NADPH to Trx, which in turn reduces thioredoxin peroxidase, methi-
onine sulfoxide reductase, ribonucleotide reductase, and other redox 
proteins (2, 3). 
Two Trx systems have been described previously in organisms 
from yeast to mammals. One is present in the cytosol and is com-
posed of TR1 (also called TXNRD1 or TrxR1) and Trx1 (4). The 
second is a mitochondrial system that consists of TR3 (also called 
TXNRD2 or TrxR2) and Trx2 (5, 6). In addition to the reduction of 
thioredoxins, TRs are capable of reducing a variety of cellular pro-
teins and compounds (7, 8). Trx systems are present in all living or-
ganisms and are often required for viability. Cytosolic as well as mi-
tochondrial Trx systems are essential for embryogenesis in mice, as 
deletion of any of their components (e.g. TR1, TR3, Trx1, or Trx2) 
has been reported to lead to embryonic lethality (9–12). 
Both TR1 and TR3 occur in multiple forms generated by alter-
native splicing (13). There are at least six alternative TR1 forms that 
differ in their N-terminal residues, including one that contains an ad-
ditional N-terminal glutaredoxin domain (14–16). Although alter-
native TR3 forms have been previously predicted (13, 17, 18), they 
have not been experimentally verifi ed. 
In this study, we describe the characterization of intracellular lo-
cation of three alternative forms of TR3, two of which are extrami-
tochondrial. Further characterization of kinetic parameters revealed 
that TR3 does not have a substrate preference for Trx2. Instead, we 
found that TR3 could effi ciently interact with Trx1 and that Trx1 is a 
major TR3 substrate in the cytosol. Thus, the function of TR3 is not 
limited to its role in mitochondria. 
Experimental Procedures 
Materials—Dulbecco’s modifi ed Eagle’s medium, fetal calf se-
rum, and antibiotic/antimicotic mixture were from Invitrogen. EDTA, 
NADPH, sodium selenite, sodium phosphate, insulin, glycerol, Tris-
HCl, HEPES, sucrose, NaCl, and Escherichia coli Trx were from 
Sigma. EDTA-free protease inhibitor mixture was from Roche Ap-
plied Science. LB medium and LB-agar medium powder were from 
Qbiogene, Inc. Horseradish peroxidase-coupled anti-rabbit and anti-
mouse antibodies and ECL detection reagents were from Amersham 
Biosciences. Anti-human Trx1 monoclonal antibodies were pur-
chased from Pharmingen, and anti-His tag antibodies from Invitro-
gen. Unless specifi ed otherwise, all other reagents were from Sigma. 
Construction of Mouse TR3, TR3a, TR3b, and TR3c Expres-
sion Vectors—Mouse (m) TR3 cDNA lacking sequences coding for 
the mitochondrial signal peptide was used as a cloning template, and 
mTR3a, mTR3b, and mTR3c cDNAs were amplifi ed from it using 
Pfu Ultra polymerase (Stratagene) and the primers shown in the sup-
plemental material. To prepare different mTR3-enhanced green fl uo-
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rescent protein (EGFP) fusion constructs, primer pairs 1, 3, 4, 5, and 
6 (forward)/2 (reverse) were used to generate mTR3a-EGFP; primer 
pair 7/2 to generate mTR3b-EGFP; primer pairs 8/2 and 9/2 to gen-
erate mTR3c-EGFP; and primer pair 10/2 to generate mTR3 without 
EGFP (without the mitochondrial signal). The PCR products were 
cloned into the EcoRI and ApaI sites of pEGFP-N2 (Clontech). In 
all mTR3 constructs, the selenocysteine (Sec) codon (UGA) was mu-
tated to a Cys codon (UGC). To generate constructs for overexpres-
sion of different mutant mTR3 proteins, the primers that are shown in 
the supplemental material were used. To prepare the mTR3 CU con-
struct, primers 11/12 and 13 were used to generate an E. coli fdhH 
selenocysteine insertion sequence (SECIS) element downstream of 
the open reading frame. Primers 11/14 and 13 were used to prepare 
the mTR3 SU construct, which also contained the bacterial SECIS 
element. These sequences were inserted into pET-28a (Novagen) at 
NheI and EcoRI sites. The sequences of all constructs were verifi ed 
by direct DNA sequencing at the Genomics Core Facility of the Uni-
versity of Nebraska. 
Cell Culture, Transfection, and Subcellular Localization of mTR3 
Isoforms—CV-1 cells were grown at 37 °C and 5% CO2 in 25-cm
2 
culture fl asks in Dulbecco’s modifi ed Eagle’s medium containing 1 
mg/ml glucose and supplemented with 10% fetal calf serum. Trans-
fections were carried out using Lipofectamine and PLUS reagent (In-
vitrogen). CV-1 cells were transfected with the constructs coding for 
different mTR3 isoforms fused to EGFP. The pEGFP-N2 vector was 
used as a control. Twenty-four hours after transfection, cells were 
washed with Opti-MEM I (Invitrogen) and subjected to staining. The 
cells were stained with MitoTracker, ER-Tracker, or LysoTracker 
(Molecular Probes) as recommended by the manufacturer. EGFP and 
Tracker fl uorescence was visualized using Olympus FV500 inverted 
confocal microscopes at the Microscopy Core Facility of the Univer-
sity of Nebraska. 
Overexpression of mTR3, Human (h) TR1, hTrx1, and Rat (r) 
Trx2 in E. coli—Bacterial expression constructs, including pET-28a-
mTR3, pET-28a-hTR1, pET-15b-hTrx1, and pET-15b-rTrx2, were 
expressed in E. coli BL21(DE3) cells. The pET-15b-rTrx2 construct 
(kindly provided by Drs. Antonio Miranda-Vizuete and Giannis 
Spyrou) codes for rTrx2 that lacks the mitochondrial signal peptide. 
Cells were grown in LB medium containing kanamycin (50 μg/ml) 
or ampicillin (100 μg/ml) at 37 °C, and protein expression was in-
duced with 0.5 mM isopropyl β-D-thiogalactopyranoside when cells 
reached ~0.6 A600 nm. For expression of Sec-containing
 proteins, the 
pET-28a-mTR3-CU, pET-28a-mTR3-SU, and pET-28a-hTR1-CU 
constructs, containing an E. coli fdhH SECIS element, were used. 
These constructs were used alone, or the cells were cotransformed 
with the pSUABC plasmid (kindly provided by Dr. Elias Arnér). 
pSUABC contains chromosomal fragments containing E. coli selA, 
selB, and selC genes under the control of their endogenous promot-
ers. Protein expression was induced by addition of 0.5 mM isopropyl 
β-D-thiogalactopyranoside when cells reached ~0.6 A600 nm. Sodium
 
selenite was added 1 h prior to induction to a fi nal concentration of 
2 μM. After the induction, cells were grown overnight at 30 °C, har-
vested by centrifugation, and stored at –80 °C until used. 
Purifi cation of Recombinant Proteins—E. coli cells were resus-
pended at 4 °C in 50 mM sodium phosphate and 150 mM NaCl (pH 
8.0) containing EDTA-free protease inhibitor mixture and sonicated. 
Following centrifugation at 14,000 rpm for 30 min at 4 °C, the super-
natant fraction was loaded onto a 10-ml TALONTM column (Clon-
tech). Recombinant proteins containing N-terminal His tags were 
eluted with a linear gradient of 20-200 mM imidazole in loading 
buffer. Fractions containing hTrx1 or rTrx2 were pooled, dialyzed 
against phosphate-buffered saline (PBS), and stored at –80 °C. Frac-
tions containing mTR3 or hTR1 were pooled, dialyzed against PBS 
(pH 7.3), and applied to a 5-ml 2’,5’-ADP-Sepharose column (Am-
ersham Biosciences) equilibrated with PBS. The bound proteins were 
eluted with 1 M NaCl in PBS, and fractions containing pure proteins 
were dialyzed against PBS and stored at –80 °C. The N-terminal His 
tags were removed using a His tag cleavage kit (Novagen). 
Antibodies and Western Blot Analyses—Polyclonal antisera 
against mTR3 and hTR1 were produced by immunization of rabbits 
with recombinant mTR3 and hTR1 proteins that contained Cys in 
place of Sec. Polyclonal antisera against hTrx1 and rTrx2 were pro-
duced by immunization of rabbits with recombinant full-length hTrx1 
and an rTrx2 form lacking the mitochondrial signal peptide. SDS-
PAGE analyses were carried out using NuPAGE Novex gels (Invitro-
gen), followed by transfer of proteins onto polyvinylidene difl uoride 
membranes. In Western blot assays, antisera were used at the follow-
ing dilutions: 1:4000 for TR3, 1:2000 for TR1, 1:2000 for Trx2 and 
Trx1, and according to the manufacturer’s instructions for hTrx1 and 
proteins containing His tags. Immunoblot signals were visualized us-
ing an ECL detection system (Amersham Biosciences). 
Thioredoxin Reductase Assay—The concentration of TRs was 
determined by measuring the fl avin absorbance at 460 nm (molar ex-
tinction coeffi cient of 11.3 mM–1 cm–1) or the absorbance at 280 nm 
and subtracting the absorbance at 310 nm (molar extinction coeffi -
cient of 65 mM–1 cm–1). For other purposes, the protein concentra-
tion was determined using the Bradford assay (Bio-Rad). TR and Trx 
activities were determined using the insulin reduction assay as de-
scribed previously (19). Reaction mixtures (500 μl) containing 3 μM 
TR3 or TR1 were used. The reaction was followed by a decrease in 
absorbance at 340 nm resulting from oxidation of NADPH. Apparent 
Km values were calculated from
 Lineweaver-Burk plots of 1/v ver-
sus 1/[S]. A molar extinction coeffi cient of 6220 M–1 cm–1 was used 
to calculate the kcat
 value. To test for inhibition of TR activity by met-
als, the proteins were incubated with the indicated concentrations of 
metal ions (Ca2+, Zn2+, and Co2+) for 5–10 min prior to adding them 
to the reaction mixtures. To study the role of EDTA, the reactions 
were carried out in the presence of the indicated concentrations of 
EDTA. 
Cell Fractionation—Cell fractionation was carried out by differ-
ential centrifugation. Briefl y, rat livers (10–20 g) or mouse livers (2–
5 g) were washed twice with ice-cold PBS and lysed on ice by 60 
Dounce strokes with a tight fi tting pestle in buffered sucrose contain-
ing 20 mM HEPES (pH 7.5), 250 mM sucrose, 1 mM EDTA, 1 mM 
EGTA, 10 mM KCl, and Complete protease inhibitor mixture (one 
tablet/10 ml; Roche Applied Science). After two centrifugation runs 
at 1000 × g to discard nuclei, mitochondria were pelleted at 10,000 × 
g, washed once, resuspended in buffered sucrose, and stored at –80 
°C. The cytosolic fraction was obtained by centrifugation of the post-
mitochondrial supernatant at 100,000 × g for 1 h. To obtain mito-
chondrial lysate, an aliquot of the mitochondrial fraction was thawed, 
resuspended in an appropriate buffer, and sonicated, and the mito-
chondrial lysate was collected by centrifugation at 10,000 × g. The 
protein content was determined by the Bradford assay. 
 Preparation of mTR3-immobilized Resins and Target Search—TR3-
immobilized resins were prepared using a previously described pro-
cedure for preparing Sepharose-based affi nity columns (20). Briefl y, 
mutant mTR3 proteins in 100 mM sodium carbonate buffer (pH 9.5) 
containing 0.5 M NaCl were incubated with cyanogen bromide-acti-
vated Sepharose 4B (Sigma) that had been swelled in the same solu-
tion for 2 h at room temperature according to the manufacturer’s in-
structions. The coupling reaction was stopped by centrifugation, and 
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unreacted side chains on the resin were blocked by incubation with 
50 mM Tris-HCl (pH 8.0) for 12 h at 4 °C. Immobilized TR3 was 
quantifi ed based on the difference between the amounts of TR3 ini-
tially used and remaining in solution after the coupling reaction. Typ-
ically, >80% of the proteins could be immobilized. To search for TR3 
targets, rat or mouse liver mitochondrial or cytosolic lysates (10 mg 
of protein) were incubated with 0.5 ml of mTR3-immobilized resin 
containing 5 mg of TR3 at 25 °C for 1 h under gentle stirring. Immo-
bilized TR3 was initially reduced with 0.2 mM NADPH for 30 min. 
The resins were washed with 50 mM Tris-HCl (pH 8.0) and 200 mM 
NaCl to remove nonspecifi cally bound proteins. The washing was re-
peated until the absorbance of the wash fraction at 280 nm was negli-
gible. Finally, the resin was suspended in 50 mM Tris-HCl (pH 8.0), 
200 mM NaCl, and 10 mM dithiothreitol (DTT) or 0.2 mM NADPH 
and incubated for 30 min at 25 °C. Eluted proteins were separated 
from the resin by centrifugation and collection of the soluble frac-
tions. The proteins were fractionated on SDS-polyacrylamide gels 
and visualized by Western blot analyses or subjected to staining with 
a Bio-Safe Coomassie or silver staining kit (Bio-Rad) and identifi ca-
tion of the proteins by tandem mass spectrometry at the Mass Spec-
trometry Facility of the University of Nebraska. 
Results 
Identifi cation and Subcellular Localization of TR3 Isoforms Gen-
erated by Alternative First Exon Splicing—By exhaustive searches 
of non-redundant and expressed sequence tag (EST) data bases, we 
detected several cDNA forms of mTR3, each represented by mul-
tiple ESTs. These forms differed in their 5’-sequences followed by 
common sequences corresponding to the core part of TR3, indicat-
ing alternative fi rst exon splicing (Figure 1). In addition to the mouse 
sequences, the corresponding forms were found in human and rat se-
quences, suggesting conservation of alternative splicing to generate 
multiple forms of TR3 in mammals. All detected TR3 cDNAs could 
be organized into three groups that resulted in unique open reading 
frames differing in their N-terminal sequences (Figure 1A). The fi rst 
form (TR3a) contains a predicted N-terminal signal peptide for mito-
chondrial targeting. It is represented by 12 ESTs in mice, 3 in rats, 13 
in humans, and 1 in dog (GenBankTM accession number DN387361 
[GenBank] ). Three mTR3 ESTs were slightly shorter than the re-
maining nine sequences containing the predicted translation initiation 
codon. However, two additional candidate initiation codons were 
found immediately downstream. Initiation of translation from any of 
the three codons was predicted to produce a mitochondrial form of 
the enzyme. The shorter form was designated as mTR3a2. Analysis 
of the Kozak consensus requirements (GCCRCCAUGG, where R = 
A or G) for translation initiation revealed that both the fi rst (CGGAC-
CAUGG) and third (GCGGCGAUGG) AUG codons have favorable 
consensus sequences and can initiate translation of mitochondrial 
mTR3. Thus, the mTR3a1 isoform is likely the major mitochondrial 
TR3 isoform in mice. 
FIGURE 1.  Alternative forms of mammalian TR3. A, amino acid sequence comparison of TR3 isoforms. The N-terminal regions of different al-
ternative forms of mouse, rat, and human TR3 are shown. The numbers in parentheses indicate the numbers of corresponding ESTs that were 
found in data bases. Identical residues within each of the three groups of sequences are highlighted. B, structural organization of mouse, rat, and 
human TR3 genes. Each numbered box represents an exon within the gene. (Only the fi rst four exons are shown.) There are three alternative 
forms of mTR3 mRNA that are differentially encoded by exons 1–3, followed by the common exon 4. The numbers between boxes indicate the 
lengths of introns (in base pairs) in the indicated genomes.
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Two other forms (TR3b and TR3c) have shorter predicted N-ter-
minal sequences and lack predicted signal sequences. TR3b is rep-
resented by eight ESTs in mouse (GenBank™ accession numbers 
CN664710 [GenBank], BY226497 [GenBank], BB843112 [Gen-
Bank], BB842317 [GenBank], BY128436 [GenBank], BY217359 
[GenBank], BY211475 [GenBank], and BB566223 [GenBank] ), four 
ESTs in rat (accession numbers CV114471 [GenBank], CB757630 
[GenBank], CB708769 [GenBank], and CK482696 [GenBank] ), 
and one EST in human (accession number DN998641 [GenBank] ). 
This form was previously predicted, but not characterized (13). TR3c 
is represented by two ESTs in mouse (accession numbers BY707998 
[GenBank] and AK008004 [GenBank] ), four ESTs in rat (accession 
numbers AI555332 [GenBank], CO393277 [GenBank], CK468797 
[GenBank], and CB759068 [GenBank] ), and two ESTs in human 
(accession numbers BX489630 [GenBank] and BE146928 [Gen-
Bank] ). It has not been described previously. The three forms utilize 
alternative fi rst exons 1–3, followed by common exon 4 (Figure 1B). 
Similar gene architectures are used to generate alternative TR3 forms 
in mouse, rat, and human genomes (Figure 1B). The order of exons is 
also conserved, although intron sequences are longer in humans com-
pared with rodents. 
The cDNAs for TR3b and TR3c were cloned in the pEGFP-N2 
expression vector to generate fusion proteins containing C-terminal 
EGFP. We also cloned the TR3a cDNA with and without the mito-
chondrial signal peptide. To increase the expression level of proteins, 
the C-terminal penultimate Sec codon was replaced with a Cys co-
don in all constructs. The four constructs were then used to assess 
subcellular localization of the three TR3 forms in CV-1 cells (Figure 
2). Consistent with the previous data for the mitochondrial form of 
TR3, the TR3a-EGFP protein was targeted to mitochondria (Figure 
2A, panels G–I). However, in the absence of the mitochondrial sig-
nal peptide, the protein was detected in the cytosol (Figure 2A, pan-
els D–F). The TR3b form has only a three-amino acid (in mice and 
rats) or four-amino acid (in humans) extension over the common se-
quence derived from exon 4. The protein with this short extension 
was cytosolic. The TR3c form has a 12-amino acid (in mice and hu-
mans) or 10-amino acid (in rats) extension and had a cytosolic loca-
tion, but the signal exhibited a non-uniform distribution. The regions 
enriched in TR3c corresponded to neither the endoplasmic reticulum 
nor lysosomes (Figure 2B, panels D–I). Overall, these data show that 
the location of TR3 is not limited to mitochondria and that at least 
two additional extramitochondrial forms exist. All TR3 forms appear 
to have unique cellular distribution properties. 
Preparation and Characterization of Sec-containing Recom-
binant mTR3 and hTR1—Sec-containing TR1 was previously ex-
pressed in E. coli from a construct in which a SECIS element de-
rived from the E. coli fdhH gene was placed downstream of the TR1 
open reading frame (16, 21–23). To express Sec-containing TR3, we 
cloned mTR3 cDNA (without the sequence coding for the mitochon-
drial signal peptide) followed by the fdhH SECIS element into the 
FIGURE 2.  Subcellular localization of alternatively spliced forms of mTR3. CV-1 cells were transfected with indicated constructs coding for 
various TR3-EGFP fusion proteins, and the cells were analyzed for EGFP fl uorescence by confocal microscopy. To identify the location of TR3 fu-
sion proteins, cells were co-stained with organelle-specifi c fl uorescent dyes (MitoTracker, ER-Tracker, and LysoTracker). A, localization of mTR3a. 
Panels A, D, and G, detection of TR3-EGFP fusion proteins by EGFP fl uorescence; panels B, E, and H, staining with MitoTracker Red; panels C, 
F, and I, merged images of MitoTracker and EGFP signals. B, localization of the mTR3b and mTR3c isoforms. Panels A, D, and G, detection of 
TR3-EGFP fusion proteins by EGFP fl uorescence; panel B, mitochondrial staining with MitoTracker Red; panel E, endoplasmic reticulum stain-
ing with ER-Tracker Blue; panel H, lysosome staining with LysoTracker Red; panels C, F, and I, merged images of the indicated organelle Track-
ers and EGFP signals.
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pET-28a(+) vector. Recombinant His-tagged TR3 was isolated by af-
fi nity chromatography on TALON resin. Sec insertion is known to 
be ineffi cient during expression of recombinant selenoproteins. We 
estimated the amount of selenium in the TR3 preparation by induc-
tively coupled plasma mass spectrometry and found that only 5% of 
the protein was in the Sec-containing form. To increase the yield of 
the Sec-containing protein, we coexpressed the TR3 construct with 
the E. coli selA, selB, and selC genes, which code for Sec synthase, 
Sec-specifi c elongation factor, and tRNASec, respectively (21, 24). In 
the case of TR3, this procedure allowed a dramatic increase in the ef-
fi ciency of Sec insertion, as the new TR3 preparation had ~0.5 eq of 
selenium, suggesting that 50% of the enzyme molecules were in the 
Sec-containing form. We repeated this experiment several times and 
found that the Seccontaining protein accounted for 41–65% of the re-
combinant enzyme preparations. We similarly cloned and prepared 
His-tagged Sec-containing hTR1, which also contained ~0.5 eq of se-
lenium when coexpressed with selA, selB, and selC. 
To our knowledge, TR3 has not been previously assayed as re-
ductant for mammalian mitochondrial Trx2, its predicted natural sub-
strate. In addition, no comparative analyses have previously been per-
formed for TR1 and TR3. We characterized the catalytic properties of 
recombinant TR3 and TR1 using a spectrophotometric assay of Trx-
dependent insulin reduction (19). We used three different recombi-
nant thioredoxins as substrates for these enzymes, including hTrx1, 
rTrx2 and E. coli Trx. Because TR3 and Trx2 are known as mito-
chondrial proteins and TR1 and Trx1 as cytosolic proteins, the ex-
pectation was that these protein pairs may show the best kinetic pa-
rameters. However, we found that the TR3/Trx2 pair had the highest 
Km and the lowest catalytic effi ciency of all
 tested enzyme-substrate 
combinations (Table 1). In addition, E. coli Trx was the best substrate 
for both mammalian TRs. Nevertheless, the differences in kinetic pa-
rameters were not dramatic, and the overall data suggest that the effi -
ciency of TR1-based Trx reduction is nearly equal for Trx1 and Trx2 
and that TR3 can reduce Trx1 and Trx2 with similar catalytic effi -
ciency. These data are consistent with the results of TR3 intracellular 
localization experiments. Because the protein is located in different 
cellular compartments, it may be able to effi ciently reduce various 
thioredoxins, not just the one in mitochondria. 
Inhibition of Thioredoxin Reductase Activity by Metal Ions— 
It was previously observed that EDTA is required for TR1 catalytic 
activity, presumably because of inhibition of the enzyme by heavy 
metal ions present in the reaction mixture (19). In addition, a previous 
study suggested that Ca2+ might be a potential inhibitor of mamma-
lian TR (25–27), although another study found no inhibitory effects 
of calcium on TR1 activity (28). The possibility remained that the 
differences observed were due to analyses of different TR isozymes. 
We tested various metal ions for their effect on the catalytic ac-
tivities of recombinant TR1 and TR3 in in vitro assays of insulin re-
duction using E. coli Trx as a substrate. The presence of EDTA was 
required for the activities of both TR1 and TR3 (Figure 3), and pro-
gressive increases in the EDTA concentration increased the activities 
of both enzymes. If the concentration of EDTA in the reaction mix-
ture was higher than 100μM (up to 1 mM tested) (data not shown), 
the enzymes were fully active. 
We next tested the effect of Ca2+ on TR1 and TR3 activities and 
further extended these studies to include Zn2+ (Figure 4). In this ex-
periment, TR1 and TR3 were preincubated for 5 min with different 
concentrations of metal ions prior to adding the enzymes to reaction 
mixtures containing 100 μM EDTA. The data clearly indicated that 
addition of Ca2+ ions had no effect on either TR1 or TR3 activity up 
to concentrations higher than the physiological levels (up to 5 mM). 
In contrast, Zn2+ completely inhibited both enzymes at 100-200 μM 
and above. Above 200 μM Zn2+ for TR1 and 300 μM Zn2+ for TR3, 
enzymes precipitated, which precluded activity assays at high con-
centrations of this metal ion. 
In the experiments described above, the recombinant TR1 and 
TR3 we used had N-terminal His tags and were purifi ed by metal af-
fi nity chromatography on a TALON resin. Because this resin contains 
chelated Co2+ ions, the possibility remained that these ions contami-
nated the protein preparations, thereby inhibiting enzyme activities. 
To test this possibility, we determined the infl uence of Co2+ on TR1 
and TR3 activities (Figure 5) and found that this metal ion had no 
signifi cant inhibitory effect, although some inhibition was observed 
at higher concentrations of Co2+. 
TABLE 1. Kinetic parameters for hTR1 and mTR3
FIGURE 3.  Effect of EDTA on TR1 
and TR3 activities. TR activity was 
assayed by following NADPH oxida-
tion in a Trx-dependent reduction of 
insulin. The indicated concentrations 
of EDTA (20–100 μM) were used in 
the reaction mixtures. A, TR1 activ-
ity; B, TR3 activity.
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To further test a possible role of the His tag as a metal chelator, 
we removed this tag from both enzymes by proteolysis with throm-
bin. We also dialyzed the substrate (E. coli Trx) overnight against 
PBS containing 1 mM EDTA. Again, we found that zinc inhibited 
TR1 and TR3 activities (Figure 6). This inhibitory effect might be 
explained by high natural affi nity of Zn2+ for dithiols. Mammalian 
TRs have two such pairs: the CXXXXC motif in the N-terminal ac-
tive site and the CU motif (where U is selenocysteine) at the C termi-
nus. Zn2+ presumably binds to one or both of these essential sites and 
completely inhibits the enzymes. 
Identifi cation of TR3 Target Proteins—The presence of TR3 in 
different cellular compartments implies that it may have multiple 
substrates. To identify protein targets of TR3, we prepared various 
mutant forms of this protein and used them as affi nity matrices. The 
following TR3 forms were prepared: (i) wild-type TR3 contain-
ing a C-terminal GCUG tetrapeptide (this sample was a 1:1 mix-
ture of the Sec-containing form and the form truncated at the Sec 
UGA codon), (ii) a mutant in which Cys in the C-terminal tetrapep-
tide was replaced with Ser (GSUG) (this form also was a 1:1 mix-
ture of the Sec-containing form and the form truncated at Ser), (iii) 
a mutant in which Sec was replaced with Cys (GCCG), (iv) a mu-
tant in which Sec in the C-terminal tetrapeptide was replaced with 
Cys and Cys was replaced with Ser (GSCG), (v) a mutant in which 
both Cys and Sec were replaced with Ser residues (GSSG), and (vi) 
a truncation mutant in which the Sec codon functioned as a stop co-
don (GC-stop) (Table 2). Each TR3 form was then linked to cyano-
gen bromide-activated Sepharose to prepare mTR3-immobilized af-
fi nity resins. We hypothesized that, by using these affi nity matrices, 
the target proteins in cell lysates could be enriched through forma-
tion of mixed disulfi de or selenenylsulfi de intermediates with im-
mobilized TR3. A schematic representation of our method is shown 
in Figure 7. 
FIGURE 4.  Effects of Ca2+ and Zn2+ 
ions on TR1 and TR3 activities. TR ac-
tivities were assayed as Trx-dependent 
reduction of insulin. TR1 and TR3 were 
fi rst preincubated with the indicated con-
centrations of metal ions (Ca2+ (A and B) 
and Zn2+ (C and D)) for 5 min, followed 
by addition of the enzymes to the reac-
tion mixture.
FIGURE 5.  Effect of Co2+ ions on TR1 
and TR3 activities. Trx-dependent insu-
lin reduction was used to assay TR ac-
tivities. TR1 and TR3 were preincubated 
with the indicated concentrations of Co2+ 
for 5 min, followed by addition of the en-
zymes to the reaction mixtures. A, TR1 
activity; B, TR3 activity.
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It was previously proposed that Sec is essential for catalysis by 
mammalian TRs (29, 30). Sec is thought to act as an attacking group 
and to reduce the active-site disulfi de in oxidized thioredoxins, form-
ing an intermediate selenenylsulfi de bond between TR and the Trx 
substrate, whereas the Cys adjacent to Sec is thought to act as a re-
solving residue, which reduces the selenenylsulfi de. Alternatively, the 
Cys might be the residue attacking the substrate, and Sec may serve 
as the resolving residue. If this is the case, one would expect to fi nd 
differences in the ability of mutant TR3 forms to bind target proteins. 
In particular, GSUG, GC, and GSCG mutants would be expected to 
stabilize the mixed selenenylsulfi de or disulfi de bonds between TR3 
and thioredoxin or others targets, whereas GCUG, GCCG, and espe-
cially GSSG mutants would be expected to either complete the reac-
tion or not interact with the substrate. 
To identify cellular targets, the immobilized mTR3 forms were 
reduced with NADPH and briefl y washed with a buffer to remove 
the excess reductant, and rat liver mitochondrial or cytosolic lysates 
were added to each resin. Following incubation and washing, the tar-
get proteins were eluted by adding a DTT-containing buffer (Figure 
8). Analysis of Coomassie Blue-stained gels revealed several protein 
bands that were present independently of the TR3 form used. There-
fore, the binding of these proteins either was nonspecifi c or did not 
involve the C-terminal tetrapeptide, suggesting that most of these 
proteins are not specifi c redox-active TR3 substrates. It is possible 
that some of these weakly bound proteins are regulators of TR3 func-
tion or can be regulated by TR3 independent of the redox function. 
Among the detected proteins, one prominent band had an ap-
proximate molecular mass of 12 kDa. Migration of this band on 
SDS-polyacrylamide gels corresponded to the predicted mass of thio-
redoxin, the substrate of TR3. It was particularly abundant in the cy-
tosolic fraction, but was also detected in the mitochondrial fraction. 
Tandem mass spectrometric sequencing of the 12-kDa protein eluted 
from various TR3 resins and in both the cytosolic and mitochondrial 
fractions identifi ed this protein as Trx1. Interestingly, we did not de-
tect peptides derived from Trx2 in either the mitochondrial or cyto-
solic fractions eluted from the TR3 columns. The trace amount of 
cytosolic Trx1 in the mitochondrial fraction could probably be ex-
plained as cytosolic contamination of the mitochondrial fraction. 
Thus, Trx1 was specifi cally enriched on the TR3 affi nity columns. 
To decrease the nonspecifi c binding of cellular proteins to the 
mTR3-immobilized resins, we extended the washing procedure and 
increased the ionic strength of the wash buffer. This procedure de-
creased the binding of many proteins to the resin; however, the 12-
kDa band remained the major protein bound to TR3 in the cytosolic 
fraction (in two samples) and was also detected as the protein en-
riched in the mitochondrial fractions (Figure 9). The 12-kDa bands 
were again subjected to sequencing and found to contain exclusively 
Trx1. It should be stressed that the TR3-C form (truncated TR3) was 
particularly effi cient in binding Trx1. This form is thought to exist in 
vivo because of truncation of TR synthesis at the UGA codon. More-
over, truncated TR1 was found to cause apoptosis in mammalian 
cells (31), although the mechanism of this effect is not known. Our 
fi nding provides a possible explanation of this effect, suggesting that 
apoptosis is promoted by the formation of stable complexes between 
truncated TRs and thioredoxins, inactivating both molecules and dis-
rupting redox homeostasis. 
To further examine the specifi city of interactions between TR3 
and target proteins in rat liver samples, we extended the studies to 
mouse liver mitochondrial and cytosolic fractions. A strong band was 
detected at ~12 kDa in the mouse liver cytosolic samples eluted from 
TR3-CU, TR3-SC, and TR3-C (but not TR3-SS) affi nity columns 
(data not shown). We also detected a weak 12-kDa band in the mouse 
liver mitochondrial samples. As in the cytosolic fractions, this pro-
tein band was enriched in the samples eluted from TR3-CU, TR3-SC, 
and TR3-C columns, but was not detected in the sample eluted from 
the TR3-SS resin. Thus, these results are consistent with those from 
the rat liver experiments. 
The mouse and rat fractions eluted from the affi nity columns 
were further subjected to Western blotting with anti-Trx1 and anti-
Trx2 polyclonal antisera. Using anti-Trx1 antibodies, we found that 
Trx1 was specifi cally bound and eluted by DTT from the resins, con-
fi rming the tandem mass spectrometric data. Also consistent with the 
mass spectrometry data, rat and mouse cytosolic Trx1 specifi cally in-
teracted with TR3-CU, TR3-SU, TR3-CC, TR3-SC, and TR3-C res-
ins and did not bind TR3-SS (Figure 10, B and D). 
In the case of Trx2 and mitochondrial samples, we detected bands 
corresponding to the molecular mass of Trx2, which were eluted 
from TR3-SC and TR-C columns (Figure 10, A and C). Co-migration 
of these bands and the control Trx2 bands detected with anti-Trx2 
antibodies in the original cytosolic and mitochondrial fractions sup-
ported their assignment as Trx bands. Unexpectedly, enrichment of 
Trx2 was poor on the TR3 columns, especially compared with that of 
Trx1, indicating that only a small fraction of Trx2 was bound to the
TABLE 2.  C-terminal mutant mTR3 proteins
FIGURE 6.  Effect of Zn2+ ions on the 
activities of TR1 and TR3 lacking His 
tags. His tags were removed from the 
recombinant proteins by thrombin cleav-
age and affi nity isolation, followed by ac-
tivity assays as shown in Figures 4 and 
5. A, TR1 activity; B, TR3 activity.
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resins, whereas the majority of Trx1 was trapped. A second band mi-
grating above the Trx2 band was also detected in two samples. The 
identity of this band is not known. 
Trx Binding Preferences of TR3—The target search experiments 
suggested that Trx1 may bind TR3 better compared with Trx2, even 
if it is present in only trace amounts in the mitochondrial fraction. To 
comparatively analyze mTR3-Trx1 and mTR3-Trx2 interactions, we 
used recombinant rTrx2 lacking the signal peptide. To test the possi-
bility that Trx2 was blocked from interacting with TR3 due to bind-
ing to an unknown protein in the mitochondrial lysate, we added re-
combinant rTrx2 to the rat liver mitochondrial fraction and applied 
it to the mTR3 affi nity columns. The eluted samples were subjected 
to Western blotting, and proteins were visualized with anti-Trx1 and 
anti-His tag monoclonal antibodies to detect His tag-containing re-
combinant Trx2. Interestingly, even when Trx2 was in excess, TR3 
only weakly interacted with this protein, whereas Trx1 was dramati-
cally enriched from essentially undetectable levels (Figure 11). Com-
parison of the detected Trx bands in the initial sample and eluted 
fractions revealed enrichment of endogenous Trx1 in the mitochon-
drial fraction on TR3 columns, but not of Trx2. These data further 
suggest that reduced TR3 interacts with Trx1 more effectively than 
with Trx2 in vitro. 
Discussion 
Human, mouse, and rat TR3 genes are similarly organized, and 
each is characterized by alternative fi rst exon splicing. We have char-
acterized three TR3 isoforms that differ in their N-terminal sequences 
in these organisms. The previously characterized mitochondrial iso-
form (TR3a) appears to be a predominant TR3 form in mammals. 
Two other isoforms (TR3b and TR3c) do not have signal peptides 
and localize to the cytosol. Although the functions of these two al-
ternative isoforms are unclear, their location outside of mitochondria 
implies that TR3 may be able to act on substrates other than Trx2. In-
deed, we identifi ed cytosolic Trx1 as the major target of TR3. During 
the preparation of this manuscript, an additional alternative splicing 
form of TR3 mRNA was identifi ed (32), which has a 3-bp deletion in 
the coding region and insertion of 1228 bp in the 3’-untranslated re-
gion between the stop codon and the SECIS element. These and the 
previous studies provide further evidence for the complexity of TR3 
expression and regulation. 
To examine in detail the catalytic properties of TR3, we prepared 
a recombinant version of this protein in E. coli, and in parallel, we 
also prepared and characterized TR1. Both proteins were expressed 
as selenoproteins as well as in the form of various mutants that dif-
FIGURE 7.  Schematic represen-
tation of the mechanism-based 
method for identifi cation of TR3 
targets. Various recombinant TR3 
forms differing in C-terminal tetrapep-
tide sequences (see Table 2) were 
immobilized to prepare the corre-
sponding affi nity resins. The immo-
bilized enzymes were reduced with 
NADPH; cell lysates were applied; 
resins were washed; and the pro-
teins specifi cally bound to the resins 
were eluted with a DTT-containing 
buffer. Left panel, putative mecha-
nism of Trx reduction by TR, in which 
the reduced selenolthiol group in TR 
provides, in a two-step process, re-
ducing equivalents to the active-site 
disulfi de in Trx; right panel, mecha-
nism-based procedure for identifi ca-
tion of TR targets. An SU mutant of 
an immobilized TR allows trapping 
of the target via a selenenylsulfi de 
bond. Subsequent addition of DTT 
elutes the target, which is then sub-
jected to a tandem mass spectrom-
etry procedure for sequencing and 
protein identifi cation.
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fered in their C-terminal sequences. Analysis of the selenium content 
of recombinant proteins verifi ed effi cient Sec insertion: ~50% of re-
combinant TR3 molecules had Sec, whereas the remaining 50% pre-
sumably corresponded to the truncated version, in which protein syn-
thesis terminated at the Sec-encoding UGA codon. As in the case of 
TR1 (21, 22), effi cient Sec insertion into TR3 required elevated ex-
pression of Sec insertion machinery, including Sec synthase, tRNA-
Sec, and SelB. 
Analysis of the specifi c activities of TR1 and TR3 revealed that 
these enzymes are functional and that their kinetic constants approx-
imately correspond to those of native enzymes isolated from animal 
tissues and cell lines (33, 34). We have determined the kinetic pa-
rameters for various TR substrates (Trx from E. coli, Trx1, and Trx2) 
(Table 1), including the fi rst Km and
 kcat values for the TR3/Trx2 pair. 
Although Trx2 has been proposed as a natural substrate of TR3 by 
analogy to the TR1/Trx1 pair, our data are the fi rst experimental ver-
ifi cation of this prediction. However, comparison of the catalytic ef-
fi ciencies of TR3 for Trx substrates revealed no preference for Trx2. 
In fact, TR3 and TR1 exhibited approximately equal activities with 
Trx1, Trx2, or E. coli Trx. This fi nding is consistent with the com-
plex localization pattern of TR3, as well as TR1, in mammalian tis-
sues and cells. 
Another important issue examined in our study was inhibition of 
TRs by divalent ions. Initial research suggested an inhibitory effect 
of calcium on TR activity in skin cells (25–27). However, which TR 
isozyme is the most abundant in skin cells and was inhibited in these 
studies is not known. Subsequently, TR1 was reported to be insensi-
tive to calcium inhibition (28, 35). However, the most recent study 
found that TR1, but not TR3, is inhibited by Ca2+ (36). Thus, the role 
of calcium in inhibition of TRs remains unresolved. 
Our present work demonstrates that the activities of TR3 and 
TR1 are not infl uenced by calcium at physiological levels of this 
metal ion. There are two major differences between our work and 
the previous studies. First, the previous inhibitory effect was ob-
served on the native TRs prepared from animal tissues. Second, 
5,5’-dithiobis(nitrobenzoic acid) was used to assay the TR activ-
ity, whereas we used a more specifi c method for assaying the activ-
ities of Sec-containing recombinant TR1 and TR3 (see “Experimen-
tal Procedures”). 
We also examined the effects of other divalent ions and found a 
strong inhibitory effect of zinc. It is well known that 1-5 mM EDTA 
is a required component in TR reaction mixtures; however, the rea-
son for this requirement is not known. There are several possible ex-
planations for the role of EDTA or other metal chelators (e.g. EGTA) 
in activating TRs. First, TR may bind metals during cell disruption. 
Second, trace amounts of heavy metals present in the buffers could 
inhibit TR activity during the purifi cation procedure. EDTA was orig-
inally used in extraction buffers during isolation of TR1 from ani-
mal tissues (33). We did not use EDTA during purifi cation of recom-
binant TRs, as the intention was to study the effects of metal ions 
and chelators on TR activities. We found that the minimal concentra-
tion of EDTA needed for maximal TR activity was 100 μM under our 
experimental conditions. We have further examined the roles Ca2+, 
Zn2+, and Co2+ ions in TR activities, but only zinc effi ciently inhib-
ited TRs. The inhibitory effect of Zn2+ could be explained by the nat-
ural affi nity of the zinc ion for protein thiol groups. The active site of 
TRs has three thiol and one selenol groups, which could potentially 
serve as zinc ligands. 
To further examine Trx2 as a TR3 substrate and to determine the 
identity of other TR3 targets, we developed a reaction mechanism-
FIGURE 8.  Identifi cation of TR3 target 
proteins. Rat liver mitochondrial and cy-
tosolic fractions were incubated with dif-
ferent mTR3-immobilized resins and 
washed, and bound proteins were eluted 
with DTT. The eluted proteins were an-
alyzed by SDS-PAGE, and Coomassie 
Blue staining was used for visualization. 
CU, SU, etc., indicate the immobilized 
forms of TR3 (as in Table 2). The molec-
ular masses of the protein standards are 
indicated in kilodaltons. A, analysis of rat 
liver mitochondrial (mito) lysate; B, anal-
ysis of rat liver cytosolic (cyto) lysate. 
The arrow indicates the position of Trx1.
FIGURE 9.  Identifi cation of Trx1 as 
a major target of TR3. Rat liver mito-
chondrial and cytosolic fractions were in-
cubated with different TR3-immobilized 
resins. Bound proteins were eluted with 
DTT and separated by SDS-PAGE. CU, 
SU, etc., indicate immobilized proteins 
(Table 2). Extensive washing procedures 
were applied as described under “Ex-
perimental Procedures.” The molecu-
lar masses of the protein standards are 
indicated in kilodaltons. A, rat liver mi-
tochondrial (mito) fraction. Silver stain-
ing is shown. B, rat liver cytosolic (cyto) 
fraction. The gel was stained with Coo-
massie Blue. The arrow indicates the 
position of Trx1.
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based procedure illustrated in Figure 7, which could also be generally 
used for determination of TR substrates. The C-terminal selenolthiol 
of TRs is thought to directly interact with oxidized Trx substrates in a 
2-electron reduction process. We hypothesized that mutation of a TR3 
residue that reduces the intermediate TR-Trx disulfi de (or selenenyl-
sulfi de) bond could stabilize the intermolecular complex, which could 
then be enriched on affi nity columns containing mutant TR3 forms. 
This hypothesis was tested by analyzing cytosolic and mitochon-
drial fractions from rat and mouse livers. Surprisingly, Trx1 was iden-
tifi ed as the major target of TR3 in both cytosolic and mitochondrial 
fractions. The failure of Trx2 to bind TR3 effectively could poten-
tially be due to differences in the redox potentials of Trx1 and Trx2 or 
to other factors. Recently, the redox potential of Trx2 was reported to 
be lower (–295 to –330 mV) than that of Trx1 (–230 mV) (37). Thus, 
in the equilibrium with TR3, most Trx2 molecules may be in the oxi-
dized form and therefore not trapped on the TR3 affi nity resins. 
Although the structures of TR1 (38), TR3 (39), and Trx2 (40) 
have been determined, little is known about the specifi c details of 
the TR-Trx interaction. Our data on the target identifi cation as well 
as the TR-Trx interaction experiments revealed that the C-terminal 
tetrapeptide is indeed the interaction partner of Trx. The mutant en-
zyme lacking both Cys and Sec in the tetrapeptide failed to inter-
act with the substrates. However, various single mutants were effec-
tive in trapping Trx1. Although these data leave open the question of 
whether Sec or Cys is the attacking residue in the reaction with Trx 
substrates, it appears that either residue can serve this function if the 
other is missing. 
The fi nding that the truncated TR3 form lacking the last two 
residues was most effi cient in binding Trx1 pointed to the potential 
mechanism by which this form contributes to apoptosis (31). Based 
on the Trx trapping experiments, it is expected that a stable TR3·Trx1 
complex (and likely other TR·Trx complexes) would be formed in 
cells in the presence of truncated TRs, thus stably binding thioredox-
ins and infl uencing redox homeostasis. 
Clearly, the substrate trapping approach could be further applied 
to other TRs. For example, the heterogeneity of TR1 is even more 
complex than that of TR3 because TR1 exists in at least six isoforms. 
Likewise, this method can be applied to search for targets of the third 
mammalian TR known as thioredoxin/glutathione reductase. This 
protein has been recently implicated in disulfi de bond formation dur-
ing sperm maturation (41). 
FIGURE 10.  Analysis of Trx1 and Trx2 interactions with TR3. Rat 
and mouse liver mitochondrial and cytosolic fractions were incubated 
with different mTR3-immobilized resins. Bound proteins were eluted 
with DTT and separated by SDS-PAGE, followed by Western blotting. 
Trx1 and Trx2 were detected with specifi c anti-Trx1 and anti-Trx2 an-
tibodies. A, rat liver mitochondrial (mito) fraction; B, rat liver cytosolic 
(cyto) fraction; C, mouse liver mitochondrial fraction; D, mouse liver 
cytosolic fraction; E, Coomassie Blue staining of samples showing 
protein loading of cytosolic and mitochondrial fractions. The positions 
of Trx1 and Trx2 are indicated by arrows.
FIGURE 11.  Analysis of the interaction between Trx2 and TR3. 
rTrx2 was added to the rat liver mitochondrial fraction, followed by in-
cubation with mTR3 resins. The bound proteins were separated as 
described under “Experimental Procedures.” A, the membrane was 
stained with anti-hTrx1 antibodies. B, the membrane was stained with 
anti-His tag antibodies. First lane, proteins eluted from the CU column; 
second lane, proteins eluted from the SS column; third lane, proteins 
eluted from the C-stop column; fourth lane, initial mitochondrial (mito) 
fraction with added rTrx2. The positions of Trx1 and Trx2 are indicated 
by arrows.
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PCR primers used in cloning and preparation of chimeric gene expression constructs 
1  mTR3a 1   5’-TATTAAGAATTCATGGCGGCGATGGTGGCCGG -3' 
2  mTR3 rew  5’-ATTAATGGGCCCGCCGCAGCAACCAGTCACAG -3' 
3  mTR3a     5’-CTGACACGCGGGACAAGGGGCGCGGCGAGTGCAGCGGGAGGG-3’ 
4  mTR3a     5’-GGCGCTTCCGGCCGCGGACACGGGCTCTGACACGCGGGACAAG-3’ 
5  mTR3a     5’-ATGTGGGCGGCGCTGCGTGGACCCAGCAGGCGCTTCCGGCCGC-3’ 
6  mTR3a     5’-ATGGCGGCGATGGTGGCCGGGCGAATGTGGGCGGCGCTGCG-3’ 
7  mTR3b     5’-GAGACTGAATTCATGGAAGGGCAGCAGAGCTTTGATCTCTTG-3’ 
8  mTR3c     5’-CAGAAGGACAGGCCTAAGCACAGGCAGCAGAGCTTTGATCTC-3’ 
9  mTR3c     5’-TACATTGAATTCATGAGCTGTGGGCAGAAGGACAGGCCTAAG-3’ 
10 mTR3(w/o) 5’-TACATTGAATTCATGGCGAGTGCAGCGGGAGGCAG -3' 
11 mTR3 CU f 5’-ATTTATAGCTAGCGCGAGTGCAGCGGGAGGGC-3’ 
12 mTR3 CU   5’-GCAGACCTGCAACCGATGTTAGCCTCAGCAACCAGTCAC-3’ 
13 mTR3 CU r 5’-TAAGAATTCGCGACCGATTGGTGCAGACCTGCAACCGATG-3’ 
14 mTR3 SU   5’-GCAGACCTGCAACCGATGTTAGCCTCAACTACCAGTCACAG-3’ 
15 mTR3 CS   5’-ACTGCGAATTCTTAGCCACTGCAACCAGTCACAG-3’ 
16 mTR3 CC   5’-ACGGCGAATTCTTAGCCGACGACACCATGCACAG-3’ 
17 mTR3 SS   5’-ACGGCGAATTCTTAGCCACTACTACCAGTCACAGTAGG-3’ 
18 mTR3 C    5’-ACGGCGAATTCTTAGCAACCAGTCACAGTAGGCTCC-3’ 
